Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Total Liabilities (2016 - 2025)

ProQR Therapeutics' Total Liabilities history spans 6 years, with the latest figure at $73.8 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 13.04% to $73.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $73.8 million, a 13.04% decrease, with the full-year FY2025 number at $73.8 million, down 13.04% from a year prior.
  • Total Liabilities hit $73.8 million in Q4 2025 for ProQR Therapeutics, down from $84.8 million in the prior quarter.
  • Over the last five years, Total Liabilities for PRQR hit a ceiling of $51.2 billion in Q1 2021 and a floor of $54.0 million in Q2 2021.
  • Historically, Total Liabilities has averaged $3.7 billion across 5 years, with a median of $102.4 million in 2022.
  • Biggest five-year swings in Total Liabilities: soared 119.15% in 2021 and later crashed 99.8% in 2022.
  • Tracing PRQR's Total Liabilities over 5 years: stood at $110.2 million in 2021, then dropped by 3.14% to $106.8 million in 2022, then decreased by 2.75% to $103.8 million in 2023, then fell by 18.28% to $84.8 million in 2024, then dropped by 13.04% to $73.8 million in 2025.
  • Business Quant data shows Total Liabilities for PRQR at $73.8 million in Q4 2025, $84.8 million in Q4 2024, and $103.8 million in Q4 2023.